4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $146,026 | – | 11,471 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 377,777 | $15,659,000 | 5.43% |
| BVF INC/IL | 1,106,070 | $45,847,000 | 1.80% |
| Eagle Health Investments LP | 50,000 | $2,073,000 | 1.33% |
| Ally Bridge Group (NY) LLC | 150,000 | $6,218,000 | 1.07% |
| Casdin Capital, LLC | 780,555 | $32,354,000 | 0.96% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $163,227,000 | 0.45% |
| Pinz Capital Management, LP | 19,900 | $825,000 | 0.38% |
| ArrowMark Colorado Holdings LLC | 1,063,744 | $44,092,000 | 0.34% |
| Perceptive Advisors | 600,256 | $24,881,000 | 0.27% |
| ACUTA CAPITAL PARTNERS, LLC | 20,000 | $829,000 | 0.23% |